US pharmaceutical company Eli Lilly reports positive results from the phase 3 ATTAIN-OSA program, in which the obesity drug Foundayo (orforglipron) was evaluated in patients with moderate to severe obstructive sleep apnea and overweight or obesity.
After 52 weeks, the drug had met the primary endpoint and significantly reduced the number of breathing pauses per hour, measured by AHI.
In patients without breathing assistance devices, AHI decreased by 43.8 percent, while the reduction was 27.5 percent in patients receiving such treatment.
Average weight loss amounted to 11.5 and 11.2 percent, respectively. The treatment also improved blood pressure and inflammatory markers.
The results were presented at the American Heart Association’s congress and simultaneously published in the medical journal JAMA.
